Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
Similar content being viewed by others 1 Introduction Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes (T2D) as a once-weekly subcutaneous (s.c.) formulation and, more recently, as a once-daily oral formulation [1]
Compounded versions, produced by compounding pharmacies, may vary in quality
Kushner P, Anderson JE, Simon J, Boye KS, Ranta K, Torcello-Gmez A, Levine JA
however, research indicates that gastrointestinal issues may be more frequent at higher dosages (25)
Its platform clearly presents plan terms and costs up front